Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy
Background and Purpose: Our previous studies demonstrated that a thiosemicarbazone iron chelator (di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone; Dp44mT) possesses potent and selective anti-cancer activity but led to cardiotoxicity at non-optimal doses. In this study, we examined the in vivo a...
| Main Authors: | , , |
|---|---|
| Format: | Journal Article |
| Published: |
John Wiley & Sons
2012
|
| Online Access: | http://hdl.handle.net/20.500.11937/27734 |
| id |
curtin-20.500.11937-27734 |
|---|---|
| recordtype |
eprints |
| spelling |
curtin-20.500.11937-277342017-09-13T15:10:07Z Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy Yu, Yu Rahmanto, Y. Richardson, D. Background and Purpose: Our previous studies demonstrated that a thiosemicarbazone iron chelator (di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone; Dp44mT) possesses potent and selective anti-cancer activity but led to cardiotoxicity at non-optimal doses. In this study, we examined the in vivo anti-tumour efficacy and tolerability of a new-generation 2-benzoylpyridine thiosemicarbazone iron chelator (2-benzoylpyridine-4,4- dimethyl-3-thiosemicarbazone; Bp44mT) administered via the oral or i.v. routes. Experimental Approach: BpT chelators were tested in vitro against human lung cancer cells (DMS-53) and in vivo in DMS-53 tumour xenografts in mice. The toxicity of Bp44mT in vivo and its effects on the expression of iron-regulated molecules involved in growth and cell cycle control were investigated. Key Results: Administration of Bp44mT by either route resulted in marked dose-dependent inhibition of tumour growth. When administered at 50 mg·kg -1 via oral gavage three times per week for 23 days, the net xenograft growth was inhibited by 75%, compared with vehicle-treated mice. Toxicological examination showed reversible alterations including slight reduction of RBC count, with a decrease of liver and splenic iron levels, which confirmed iron chelation in vivo. Importantly, in contrast to Dp44mT, the chelator-treated mice did not show cardiac histological abnormalities. There was also no significant weight loss in mice, suggesting oral administration of Bp44mT was well tolerated. Conclusions and Implications:This is the first study to show that Bp44mT can be given orally with potent anti-tumour efficacy. Oral administration of a novel and effective chemotherapeutic agent provides the benefits of convenience for chronic dosing regimens. 2012 Journal Article http://hdl.handle.net/20.500.11937/27734 10.1111/j.1476-5381.2011.01526.x John Wiley & Sons unknown |
| repository_type |
Digital Repository |
| institution_category |
Local University |
| institution |
Curtin University Malaysia |
| building |
Curtin Institutional Repository |
| collection |
Online Access |
| description |
Background and Purpose: Our previous studies demonstrated that a thiosemicarbazone iron chelator (di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone; Dp44mT) possesses potent and selective anti-cancer activity but led to cardiotoxicity at non-optimal doses. In this study, we examined the in vivo anti-tumour efficacy and tolerability of a new-generation 2-benzoylpyridine thiosemicarbazone iron chelator (2-benzoylpyridine-4,4- dimethyl-3-thiosemicarbazone; Bp44mT) administered via the oral or i.v. routes. Experimental Approach: BpT chelators were tested in vitro against human lung cancer cells (DMS-53) and in vivo in DMS-53 tumour xenografts in mice. The toxicity of Bp44mT in vivo and its effects on the expression of iron-regulated molecules involved in growth and cell cycle control were investigated. Key Results: Administration of Bp44mT by either route resulted in marked dose-dependent inhibition of tumour growth. When administered at 50 mg·kg -1 via oral gavage three times per week for 23 days, the net xenograft growth was inhibited by 75%, compared with vehicle-treated mice. Toxicological examination showed reversible alterations including slight reduction of RBC count, with a decrease of liver and splenic iron levels, which confirmed iron chelation in vivo. Importantly, in contrast to Dp44mT, the chelator-treated mice did not show cardiac histological abnormalities. There was also no significant weight loss in mice, suggesting oral administration of Bp44mT was well tolerated. Conclusions and Implications:This is the first study to show that Bp44mT can be given orally with potent anti-tumour efficacy. Oral administration of a novel and effective chemotherapeutic agent provides the benefits of convenience for chronic dosing regimens. |
| format |
Journal Article |
| author |
Yu, Yu Rahmanto, Y. Richardson, D. |
| spellingShingle |
Yu, Yu Rahmanto, Y. Richardson, D. Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy |
| author_facet |
Yu, Yu Rahmanto, Y. Richardson, D. |
| author_sort |
Yu, Yu |
| title |
Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy |
| title_short |
Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy |
| title_full |
Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy |
| title_fullStr |
Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy |
| title_full_unstemmed |
Bp44mT: An orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy |
| title_sort |
bp44mt: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy |
| publisher |
John Wiley & Sons |
| publishDate |
2012 |
| url |
http://hdl.handle.net/20.500.11937/27734 |
| first_indexed |
2018-09-06T21:13:18Z |
| last_indexed |
2018-09-06T21:13:18Z |
| _version_ |
1610894171869020160 |